Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.

Imbruvica faces challenges on multiple fronts.

Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?

Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.

The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.

As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.